» Articles » PMID: 12778077

Mechanism of IL-12 Mediated Alterations in Tumour Blood Vessel Morphology: Analysis Using Whole-tissue Mounts

Overview
Journal Br J Cancer
Specialty Oncology
Date 2003 Jun 5
PMID 12778077
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

New blood vessel formation within tumours is a critical feature for tumour growth. A major limitation in understanding this complex process has been the inability to visualise and analyse vessel formation. Here, we report on the development of a whole-tissue mount technique that allows visualisation of vessel structure. Mice expressing green fluorescent protein (GFP) made it possible to easily see GFP(+) vessels within non-GFP-expressing B16 melanoma tumours. The small fragments of tumour used in this technique were also effectively stained with fluorescent probe-conjugated antibodies, allowing characterisation of the vessels based on surface marker phenotype. The vessels within tumour tissue were much more irregular and tortuous compared to those within surrounding normal muscle. B16 tumours stably transfected with the genes for IL-12 were used to assess the effects of this cytokine on tumour growth and vessel formation. The IL-12-expressing tumours grew more slowly and had much smaller blood vessels than the large, webbed vessels characteristic of the parental tumours, effects that were dependent on interferon gamma (IFN-gamma). Vessels in the parental tumours were found to express VEGFR-3, the receptor for VEGF-C and VEGF-D. Expression of this receptor by the endothelial cells of the blood vessels was lost in the cytokine expressing tumours, thus suggesting a mechanism for the antiangiogenic effects of IL-12. The combination of the whole mount technique and the GFP transgenic mice provides a powerful method for visualising tumour vasculature and characterising the effects of agents such as cytokines.

Citing Articles

Hacking the Immune Response to Solid Tumors: Harnessing the Anti-Cancer Capacities of Oncolytic Bacteria.

Roe J, Seely K, Bussard C, Eischen Martin E, Mouw E, Bayles K Pharmaceutics. 2023; 15(7).

PMID: 37514190 PMC: 10384176. DOI: 10.3390/pharmaceutics15072004.


Safety levels of systemic IL-12 induced by cDNA expression as a cancer therapeutic.

Savid-Frontera C, Viano M, Baez N, Reynolds D, Matellon M, Young H Immunotherapy. 2021; 14(2):115-133.

PMID: 34783257 PMC: 8739399. DOI: 10.2217/imt-2021-0080.


Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma.

Han B, Murphy J, Qin S, Ye J, Uccello T, Garrett-Larsen J Immunol Invest. 2020; 49(7):808-823.

PMID: 32498585 PMC: 7904097. DOI: 10.1080/08820139.2020.1765795.


CXCL10 stabilizes T cell-brain endothelial cell adhesion leading to the induction of cerebral malaria.

Sorensen E, Lian J, Ozga A, Miyabe Y, Ji S, Bromley S JCI Insight. 2018; 3(8).

PMID: 29669942 PMC: 5931132. DOI: 10.1172/jci.insight.98911.


Expression of CNPY2 in mouse tissues: quantification and localization.

Hatta K, Guo J, Ludke A, Dhingra S, Singh K, Huang M PLoS One. 2014; 9(11):e111370.

PMID: 25393402 PMC: 4230931. DOI: 10.1371/journal.pone.0111370.


References
1.
Weidner N, Folkman J . Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol. 1996; :167-90. View

2.
McAdam A, Pulaski B, Storozynsky E, Yeh K, Sickel J, Frelinger J . Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell Immunol. 1995; 165(2):183-92. DOI: 10.1006/cimm.1995.1204. View

3.
Folkman J . Tumor angiogenesis in women with node-positive breast cancer. Cancer J Sci Am. 1995; 1(2):106-8. View

4.
Trinchieri G, Scott P . Interleukin-12: basic principles and clinical applications. Curr Top Microbiol Immunol. 1999; 238:57-78. DOI: 10.1007/978-3-662-09709-0_4. View

5.
Rakhmilevich A, Turner J, Ford M, McCabe D, Sun W, Sondel P . Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci U S A. 1996; 93(13):6291-6. PMC: 39015. DOI: 10.1073/pnas.93.13.6291. View